136 related articles for article (PubMed ID: 35901496)
41. A Systematic Review of Published Physiologically-based Kinetic Models and an Assessment of their Chemical Space Coverage.
Thompson CV; Firman JW; Goldsmith MR; Grulke CM; Tan YM; Paini A; Penson PE; Sayre RR; Webb S; Madden JC
Altern Lab Anim; 2021 Sep; 49(5):197-208. PubMed ID: 34836462
[TBL] [Abstract][Full Text] [Related]
42. Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization.
Wambaugh JF; Wetmore BA; Ring CL; Nicolas CI; Pearce RG; Honda GS; Dinallo R; Angus D; Gilbert J; Sierra T; Badrinarayanan A; Snodgrass B; Brockman A; Strock C; Setzer RW; Thomas RS
Toxicol Sci; 2019 Dec; 172(2):235-251. PubMed ID: 31532498
[TBL] [Abstract][Full Text] [Related]
43. Physiologically based kinetic modelling predicts the in vivo relative potency of riddelliine N-oxide compared to riddelliine in rat to be dose dependent.
Widjaja F; Wesseling S; Rietjens IMCM
Arch Toxicol; 2022 Jan; 96(1):135-151. PubMed ID: 34669010
[TBL] [Abstract][Full Text] [Related]
44. Incorporating renal excretion via the OCT2 transporter in physiologically based kinetic modelling to predict in vivo kinetics of mepiquat in rat.
Noorlander A; Wesseling S; Rietjens IMCM; van Ravenzwaay B
Toxicol Lett; 2021 Jun; 343():34-43. PubMed ID: 33639197
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
46. Physiologically based kinetic (PBK) modeling as a new approach methodology (NAM) for predicting systemic levels of gut microbial metabolites.
Stevanoska M; Folz J; Beekmann K; Aichinger G
Toxicol Lett; 2024 May; 396():94-102. PubMed ID: 38685289
[TBL] [Abstract][Full Text] [Related]
47. Applicability of generic PBK modelling in chemical hazard assessment: A case study with IndusChemFate.
Fragki S; Piersma AH; Westerhout J; Kienhuis A; Kramer NI; Zeilmaker MJ
Regul Toxicol Pharmacol; 2022 Dec; 136():105267. PubMed ID: 36367522
[TBL] [Abstract][Full Text] [Related]
48. Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.
Fragki S; Hoogenveen R; van Oostrom C; Schwillens P; Piersma AH; Zeilmaker MJ
Toxicology; 2022 Jan; 465():153060. PubMed ID: 34871708
[TBL] [Abstract][Full Text] [Related]
49. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
Gertz M; Houston JB; Galetin A
Drug Metab Dispos; 2011 Sep; 39(9):1633-42. PubMed ID: 21632965
[TBL] [Abstract][Full Text] [Related]
50. Physiologically-Based Kinetic Modeling of Intravenously Administered Gold (Au) Nanoparticles.
Minnema J; Vandebriel RJ; Boer K; Klerx W; De Jong WH; Delmaar CJE
Small; 2023 May; 19(21):e2207326. PubMed ID: 36828794
[TBL] [Abstract][Full Text] [Related]
51. Physiologically based kinetic modeling of the bioactivation of myristicin.
Al-Malahmeh AJ; Al-Ajlouni A; Wesseling S; Soffers AE; Al-Subeihi A; Kiwamoto R; Vervoort J; Rietjens IM
Arch Toxicol; 2017 Feb; 91(2):713-734. PubMed ID: 27334372
[TBL] [Abstract][Full Text] [Related]
52. A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.
Ye M; Nagar S; Korzekwa K
Biopharm Drug Dispos; 2016 Apr; 37(3):123-41. PubMed ID: 26531057
[TBL] [Abstract][Full Text] [Related]
53. Integrating
Chen J; Noorlander A; Wesseling S; Bouwmeester H; Kramer NI; Rietjens IMCM
Environ Sci Technol; 2023 Aug; 57(30):10974-10984. PubMed ID: 37478462
[TBL] [Abstract][Full Text] [Related]
54. Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding.
Da-Silva F; Boulenc X; Vermet H; Compigne P; Gerbal-Chaloin S; Daujat-Chavanieu M; Klieber S; Poulin P
J Pharm Sci; 2018 Jul; 107(7):1957-1972. PubMed ID: 29524447
[TBL] [Abstract][Full Text] [Related]
55. Physiologically-Based Kinetic Modeling Predicts Similar In Vivo Relative Potency of Senecionine N-Oxide for Rat and Human at Realistic Low Exposure Levels.
Widjaja F; Alhejji Y; Yangchen J; Wesseling S; Rietjens IMCM
Mol Nutr Food Res; 2023 Feb; 67(4):e2200293. PubMed ID: 36478522
[TBL] [Abstract][Full Text] [Related]
56. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
Poirier A; Funk C; Scherrmann JM; Lavé T
Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
[TBL] [Abstract][Full Text] [Related]
57. Use of an in vitro-in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine.
Ning J; Chen L; Strikwold M; Louisse J; Wesseling S; Rietjens IMCM
Arch Toxicol; 2019 Mar; 93(3):801-818. PubMed ID: 30661089
[TBL] [Abstract][Full Text] [Related]
58. Nano- and microplastic PBK modeling in the context of human exposure and risk assessment.
Wardani I; Hazimah Mohamed Nor N; Wright SL; Kooter IM; Koelmans AA
Environ Int; 2024 Apr; 186():108504. PubMed ID: 38537584
[TBL] [Abstract][Full Text] [Related]
59. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
60. Development of a Generic Physiologically Based Kinetic Model to Predict In Vivo Uterotrophic Responses Induced by Estrogenic Chemicals in Rats Based on In Vitro Bioassays.
Zhang M; van Ravenzwaay B; Rietjens IMCM
Toxicol Sci; 2020 Jan; 173(1):19-31. PubMed ID: 31626307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
